# Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

> **NCT02511613** · PHASE2 · WITHDRAWN · sponsor: **Ohr Pharmaceutical Inc.**

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Squalamine Lactate Ophthalmic Solution, 0.2%
- **DRUG:** Placebo Ophthalmic Solution
- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT02511613
- **Lead sponsor:** Ohr Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2017-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511613, "Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02511613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*